OMB APPROVAL
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
OMB Number: 3235-0058
Expires: April 30, 2009
Estimated average burden hours per response . . . 2.50
SEC FILE NUMBER
001-32639
CUSIP NUMBER 563118207
 
 
(Check one):
 
o Form 10-K
 
o Form 20-F
 
o Form 11-K
 
x Form 10-Q
 
o Form 10-D
 
 
o Form N-SAR
 
o Form N-CSR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Period Ended:
September 30, 2008
 
 
o Transition Report on Form 10-K
 
 
 
 
 
 
o Transition Report on Form 20-F
 
 
 
 
 
 
o Transition Report on Form 11-K
 
 
 
 
 
 
o Transition Report on Form 10-Q
 
 
 
 
 
 
o Transition Report on Form N-SAR
 
 
 
 
 
 
For the Transition Period Ended:
 
                       
 
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION
 
MANHATTAN PHARMACEUTICALS, INC.
Full Name of Registrant
 
N/A
Former Name if Applicable
 
48 WALL STREET, SUITE 1100
Address of Principal Executive Office (Street and Number)
 
NEW YORK, NY 10005
City, State and Zip Code
 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III — NARRATIVE
 
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
 
SEC 1344 (03-05)
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
 
 
 

Manhattan Pharmaceuticals, Inc. (the “Company”) is unable to timely file its Quarterly Report on Form 10-Q for the three month period ended September 30, 2008 (the “Form 10-Q”) without unreasonable effort or expense. The principal reason for the delay in filing the Form 10-Q is that additional time is required in order for the Company to analyze additional information to complete the disclosure in the Company’s financial statements and the Form 10-Q.
 
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
 
(1)
 
Name and telephone number of person to contact in regard to this notification
 
 
Michael McGuinness
 
(212)
 
492-8741
 
 
(Name)
 
(Area Code)
 
(Telephone Number)
 
 
 
(2)
 
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
 
 
 
 
 
 
 
 
 
x Yes    o No
 
 
 
 
 
 
 
(3)
 
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 
 
 
 
 
 
 
 
oYes    x  No
 
 
 
 
 
 
 
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
 
MANHATTAN PHARMACEUTICALS, INC.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
       
MANHATTAN PHARMACEUTICALS, INC.
         
Date:
November 14, 2008
 
By:
 /s/ Michael McGuinness
 
 
 
 
Michael McGuinness
 
 
 
 
Chief Financial Officer and Chief Operating Officer
           
 
 
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
 
 
ATTENTION
 
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).